Relationship between serum apolipoproteins levels and retinopathy risk in subjects with type 2 diabetes mellitus

Zhang, Qianjin; Hu, Jin-E; Hu, Yichuan; Ding, Ying; Zhu, Jingjing; Zhuang, Changjiang

doi:10.1007/s00592-018-1136-9

Cited by 16 publications

(28 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Elevated ApoA1 levels could be a protective factor against DR, where a baseline serum level of ApoAI ≥ 7.4 lmol/L was associated with a decreased risk of DR. In contrast, baseline levels of ApoCIII ≥ 6.3 lmol/L and ApoCIIIto-ApoAI ratio ≥0.9 correlated with an increased risk of DR (Zhang et al, 2018). Further studies by Chung et al and Moosaie et al also report an inverse relationship between ApoA1 and DR severity and a positive correlation of ApoB/ApoAI ratio to DR severity (Chung et al, 2019;Moosaie et al, 2020).…”

Section: Enzyme Inhibitorsmentioning

confidence: 89%

“…By contrast, circulating ApoAI levels are inversely associated with DR, according to severity, in several studies of people with diabetes (Sasongko et al, 2011;Hu et al, 2012;Moosaie et al, 2020). A recent study by Zhang et al, (2018) further confirmed the association between circulating ApoAI and risk of DR but also found a positive relationship for ApoCIII levels. Elevated ApoA1 levels could be a protective factor against DR, where a baseline serum level of ApoAI ≥ 7.4 lmol/L was associated with a decreased risk of DR.…”

Section: Enzyme Inhibitorsmentioning

confidence: 91%

“…Elevated ApoA1 levels could be a protective factor against DR, where a baseline serum level of ApoAI ≥ 7.4 μmol/L was associated with a decreased risk of DR. In contrast, baseline levels of ApoCIII ≥ 6.3 μmol/L and ApoCIII‐to‐ApoAI ratio ≥0.9 correlated with an increased risk of DR (Zhang et al., 2018). Further studies by Chung et al.…”

Section: Markersmentioning

confidence: 99%

See 2 more Smart Citations

Diagnostic circulating biomarkers to detect vision‐threatening diabetic retinopathy: Potential screening tool of the future?

Frudd

Sivaprasad

Raman

et al. 2021

Acta Ophthalmologica

View full text Add to dashboard Cite

With the increasing prevalence of diabetes in developing and developed countries, the socio‐economic burden of diabetic retinopathy (DR), the leading complication of diabetes, is growing. Diabetic retinopathy (DR) is currently one of the leading causes of blindness in working‐age adults worldwide. Robust methodologies exist to detect and monitor DR; however, these rely on specialist imaging techniques and qualified practitioners. This makes detecting and monitoring DR expensive and time‐consuming, which is particularly problematic in developing countries where many patients will be remote and have little contact with specialist medical centres. Diabetic retinopathy (DR) is largely asymptomatic until late in the pathology. Therefore, early identification and stratification of vision‐threatening DR (VTDR) is highly desirable and will ameliorate the global impact of this disease. A simple, reliable and more cost‐effective test would greatly assist in decreasing the burden of DR around the world. Here, we evaluate and review data on circulating protein biomarkers, which have been verified in the context of DR. We also discuss the challenges and developments necessary to translate these promising data into clinically useful assays, to detect VTDR, and their potential integration into simple point‐of‐care testing devices.

show abstract

Section: Enzyme Inhibitorsmentioning

confidence: 89%

Section: Enzyme Inhibitorsmentioning

confidence: 91%

Section: Markersmentioning

confidence: 99%

See 1 more Smart Citation

Diagnostic circulating biomarkers to detect vision‐threatening diabetic retinopathy: Potential screening tool of the future?

Frudd

Sivaprasad

Raman

et al. 2021

Acta Ophthalmologica

View full text Add to dashboard Cite

show abstract

“…With in-depth investigations, the serum levels of traditional lipid profiles slightly increased, but the apolipoproteins collectively improved the area by approximately 8%. A combination of traditional lipid profiles and apolipoproteins showed improvement by more than 7% [72].…”

Section: Apolipoproteinsmentioning

confidence: 99%

Emerging insights into the relationship between hyperlipidemia and the risk of diabetic retinopathy

Chou

et al. 2020

Lipids Health Dis

View full text Add to dashboard Cite

Hyperlipidemia is correlated with a series of health problems. Notably, aside from its established role in promoting cardiovascular morbidity and mortality, hyperlipidemia has also been considered for modulating the risk and the severity of multiple metabolic disorders. According to the results of epidemiologic investigations, several certain circulating lipoprotein species are correlated with the prevalence of diabetic retinopathy, suggesting that the physiological and pathological role of these lipoproteins is analogous to that observed in cardiovascular diseases. Furthermore, the lipid-lowering treatments, particularly using statin and fibrate, have been demonstrated to ameliorate diabetic retinopathy. Thereby, current focus is shifting towards implementing the protective strategies of diabetic retinopathy and elucidating the potential underlying mechanisms. However, it is worth noting that the relationship between major serum cholesterol species and the development of diabetic retinopathy, published by other studies, was inconsistent and overall modest, revealing the relationship is still not clarified. In this review, the current understanding of hyperlipidemia in pathogenesis of diabetic retinopathy was summarized and the novel insights into the potential mechanisms whereby hyperlipidemia modulates diabetic retinopathy were put forward.

show abstract

“…The final glycation products that accumulate in hyperglycemia play an important role in the DR pathogenesis [8]. On the other hand, elevated levels of apoCIII and apoE lipoproteins are also the risk factors for DR [9]. Presence of hypertension is also important [10].…”

Section: The Main Causes Of Sight Lossmentioning

confidence: 99%

Plasmapheresis in Ophthalmology

Voinov

Karchevscy

2019

CTOY

View full text Add to dashboard Cite

Loss of sight is one of the most severe disabling factors in human. The total number of such people is known to account for millions worldwide. In North America alone more than 1 million are completely blind and about 14 million have some degree of sight loss. There are many different diseases that lead to sight loss such as diabetic retinopathy, senile macular degeneration, various types of autoimmune retinopathy, optic nerves damage and many others. As a rule, they cannot be corrected with glasses, and not always amenable to drug therapy. Often the cause of these diseases is accumulation of various autoantibodies and other metabolites, the molecules large size of which does not allow them to be excreted by the kidneys and the fact of their accumulation indicates impossibility of their removal with help of drug therapy. It makes us resort to such method of their direct removal from the body as plasmapheresis and the aim of this study is to justify its use in ophthalmology.

show abstract

Relationship between serum apolipoproteins levels and retinopathy risk in subjects with type 2 diabetes mellitus

Abstract: Elevated level of apoAI might be a protective factor for diabetic retinopathy. Increased levels of apoCIII, apoE, apoCIII-to-apoAI and apoE-to-apoAI ratios might be risk factors for this complication.

Cited by 16 publications

References 32 publications

Diagnostic circulating biomarkers to detect vision‐threatening diabetic retinopathy: Potential screening tool of the future?

Diagnostic circulating biomarkers to detect vision‐threatening diabetic retinopathy: Potential screening tool of the future?

Emerging insights into the relationship between hyperlipidemia and the risk of diabetic retinopathy

Plasmapheresis in Ophthalmology

Contact Info

Product

Resources

About